Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient interviews on hemophilia B gene therapy after HOPE-B
NL-OMON58200Not yet recruiting
- Sponsor
- CSL Limited
- Start
- Nov 2025
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Limited. Primary endpoints: Changes in health-related quality of life since gene therapy infusion and Treatment satisfaction, hopes, and concerns. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON58200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58200.